Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIKI-PT nebulized ketamine pharmacokinetic study in post-operative and trauma ICU patients
ACTRN12625000171415Phase 2Not yet recruiting
- Sponsor
- The University of Queensland
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in acute pain, sponsored by The University of Queensland. Primary endpoints: Plasma pharmacokinetics of single-dose nebulized ketamine, Urine creatinine clearance and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
acute pain
Beyond the preview
Go deeper on ACTRN12625000171415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000171415.